Influenza antivirals

Quick revision

Four neuraminidase inhibitors (oseltamivir, zanamivir, peramivir, and — historically — laninamivir) block the enzyme that releases new influenza virions from an infected cell, while baloxavir marboxil works earlier by blocking the viral polymerase's cap-snatching endonuclease; both drug families only help if started within about 48 hours of symptom onset, and the two adamantanes are no longer recommended because of resistance.

• Oseltamivir (Tamiflu, oral), zanamivir (Relenza, inhaled) and peramivir (Rapivab, IV) are neuraminidase inhibitors: they block the viral neuraminidase enzyme that cleaves sialic acid so newly made virus particles can be released from the infected cell surface. (1) (2) (3)
• Baloxavir marboxil (Xofluza) works differently: it inhibits the endonuclease activity of the viral polymerase acidic (PA) protein, blocking the cap-snatching step the virus needs to transcribe its own mRNA, which stops replication earlier in the viral life cycle than a neuraminidase inhibitor does. (4)
• All four current agents share the same core evidence pattern: benefit is greatest, and treatment is indicated, only when started within 48 hours of symptom onset, in patients with acute uncomplicated influenza A or B. (1) (4) (5)
• The oseltamivir-resistance mutation H275Y in the neuraminidase gene became the dominant strain characteristic of circulating 2008 seasonal H1N1 influenza, found in more than 99% of US isolates that year, before that specific strain was later displaced by the 2009 pandemic lineage. (1)
• Baloxavir resistance arises through PA substitutions at position 38 (commonly I38T), which were detected in treatment-emergent isolates from clinical trials at meaningfully higher frequency in children (about 20-28%) than in adults (about 4.5-11%). (4)
• The adamantanes amantadine and rimantadine block the influenza A M2 ion channel, but the CDC states plainly that they are not recommended for treatment or chemoprophylaxis because of high levels of resistance among circulating influenza A viruses; neither adamantane works against influenza B at all, because influenza B's M2-equivalent protein is structurally different. (5) (6)
• Zanamivir is inhaled and is specifically not recommended for patients with underlying airway disease such as asthma or COPD because of a risk of serious bronchospasm. (2)
• Baloxavir's absorption is reduced by polyvalent cations, so it should not be taken with dairy products, calcium-fortified beverages, or polyvalent-cation-containing laxatives or antacids. (4)

Overview

Influenza antivirals are narrow-spectrum by design: unlike a broad antibacterial, they act against essentially one virus family, and the evidence supporting all of them rests on the same time-sensitive premise — that blocking a step in the influenza replication cycle only meaningfully shortens illness or prevents transmission when the drug is on board early. Every current label repeats a version of the same instruction: begin treatment within 48 hours of symptom onset in a patient with acute, uncomplicated influenza A or B infection. (1) (4) (5)

Two mechanistically distinct families do the current heavy lifting. The neuraminidase inhibitors — oral oseltamivir, inhaled zanamivir, and intravenous peramivir — block the viral neuraminidase enzyme that a newly assembled virus particle needs to cut itself free from the sialic acid on the surface of the cell it just infected. Baloxavir marboxil, approved more recently, acts earlier in the cycle: it inhibits the endonuclease activity of the influenza polymerase acidic (PA) protein, the enzyme the virus uses to 'snatch' a cap structure from host mRNA so it can transcribe its own genes. Blocking that cap-snatching step stops the virus before it has made new proteins at all, rather than stopping the finished particle from leaving the cell. (1) (2) (3) (4)

A third, older family — the adamantanes amantadine and rimantadine — block the influenza A M2 ion channel and once had a real place in seasonal flu treatment. They no longer do. The CDC states directly that amantadine and rimantadine are not recommended for antiviral treatment or chemoprophylaxis of influenza because of high levels of resistance among circulating influenza A viruses, a resistance pattern first documented at scale during the 2005-2006 season and never reversed. Neither adamantane has activity against influenza B at all, because influenza B's equivalent protein is structurally different from the M2 channel the drugs target. The class is retained here for historical and exam purposes, not as a current treatment recommendation. (5) (6)

Route of administration is a genuine, clinically relevant point of difference within the modern class, not a minor detail. Oseltamivir is oral and can be used from 2 weeks of age for treatment; zanamivir is a dry-powder oral inhalation delivered by a Diskhaler device and is avoided in patients with reactive airway disease; peramivir is given as a single intravenous infusion, which matters for a patient who cannot swallow or inhale reliably; and baloxavir is a single oral dose, an adherence advantage the multi-day regimens do not share. (1) (2) (3) (4)

Classification and drug examples

The class is best organised by mechanism and target: neuraminidase inhibitors act late in the replication cycle at the point of viral release, the cap-dependent endonuclease inhibitor acts early at the point of viral transcription, and the adamantanes — retained for historical and exam context only — act at viral uncoating and are no longer recommended for use.

Mechanism of action

Influenza's replication cycle offers several druggable steps, and the two currently recommended drug families act on two different ones. Neuraminidase inhibitors act at the very end of the cycle, after new virions have already assembled at the infected cell's surface: the viral neuraminidase enzyme normally cleaves sialic acid residues so a finished virion can detach and go on to infect other cells, and blocking that enzyme leaves virions clumped uselessly at the surface instead of spreading. Baloxavir marboxil acts far earlier, before any new viral protein has been made: after the virus enters a cell and its genome reaches the nucleus, the viral RNA polymerase's PA subunit has to 'snatch' a short capped fragment from a host pre-mRNA to prime its own transcription, and baloxavir's active metabolite, baloxavir acid, blocks the endonuclease that performs that snatching step.

Molecular target

Viral neuraminidase (oseltamivir, zanamivir, peramivir); the polymerase acidic (PA) endonuclease of the viral RNA polymerase complex (baloxavir marboxil); the M2 ion channel of influenza A (adamantanes, not currently recommended)

Pharmacodynamic effect

Functionally virustatic — these drugs suppress viral replication and spread within an infected host rather than eliminating already-formed virus, which is part of why the time window for starting treatment matters so much

Effect kinetics

Effect depends entirely on how early in the illness the drug is started; benefit measured in this class is a reduction in the duration of symptoms and, for baloxavir, in the duration of infectious virus shedding, not sterilisation of an established infection

1. The virus enters a respiratory epithelial cell and releases its genome

   Influenza binds sialic acid receptors on the host cell surface, is endocytosed, and its ribonucleoprotein complexes are released into the cytoplasm and trafficked to the nucleus, where transcription and replication of the segmented RNA genome take place. (4)

2. Baloxavir acts here: the viral polymerase needs a capped RNA primer

   The viral RNA-dependent RNA polymerase's PA subunit has endonuclease activity that cleaves a short capped fragment from host pre-mRNA (cap-snatching) to use as a primer for viral mRNA synthesis; baloxavir marboxil's active metabolite inhibits this endonuclease, blocking viral mRNA transcription before any new viral protein is made. (4)

3. If transcription proceeds, the virus assembles new virions at the cell surface

   Newly made viral proteins and genome segments assemble into new virions that bud from the infected cell's plasma membrane, still tethered to the cell surface by sialic acid interactions with the viral haemagglutinin. (1)

4. Neuraminidase inhibitors act here: release of the new virion is blocked

   The viral neuraminidase enzyme normally cleaves the sialic acid that tethers a budding virion to the cell (and to other virions), letting it detach and go on to infect further cells; oseltamivir carboxylate (oseltamivir's active metabolite), zanamivir and peramivir all competitively inhibit this enzyme, so virions remain aggregated at the cell surface instead of spreading. (1) (2) (3)

5. The adamantanes act at an earlier, now largely irrelevant step: viral uncoating

   Amantadine and rimantadine block the influenza A M2 protein, an ion channel the virus needs early in entry to acidify its interior and release its genome from the matrix protein (uncoating); this mechanism only ever applied to influenza A, and it is now defeated by a resistance mutation present in essentially all circulating strains. (6) (5)

Spectrum of activity

Spectrum in this class is not about a range of different microbial genera the way it is for an antibacterial — every drug here targets influenza specifically — but there is a real spectrum distinction between influenza A and influenza B coverage, and a further distinction in which viral subtypes and resistance genotypes each mechanism actually reaches.

Major clinical uses

Pharmacokinetics

• This page gives no dose regimens by design. Renal-impairment dosing for oseltamivir, peramivir and zanamivir, and weight-based dosing for baloxavir, belong in a current prescribing reference used by the treating clinician.
• Route is a real pharmacokinetic and practical differentiator in this class: oseltamivir's oral bioavailability supports outpatient use across a wide age range, zanamivir's inhaled route keeps systemic exposure low but requires intact inspiratory technique, and peramivir's IV route removes the absorption question entirely for a patient who cannot swallow or inhale reliably. (1) (2) (3)

Adverse effects

Common

• Nausea and vomiting: The most commonly reported adverse reactions with oseltamivir in treatment studies; vomiting was the only reaction reported at a frequency of more than 1% in some paediatric populations. (1)
• Headache: Reported with oseltamivir and also among the more common reactions with baloxavir marboxil. (1) (4)
• Diarrhoea, bronchitis, sinusitis: The most common adverse reactions reported with baloxavir marboxil in clinical trials, each in the low single-digit percentages. (4)

Serious adverse effects

• Neuropsychiatric events (delirium, abnormal behaviour): Postmarketing reports describe delirium and abnormal behaviour leading to injury in patients, predominantly paediatric, taking oseltamivir; the label specifically recommends closely monitoring patients with influenza for signs of abnormal behaviour during treatment. Patients and caregivers are advised to seek medical attention promptly if unusual behaviour develops during treatment. (1)
• Serious hypersensitivity, including anaphylaxis and angioedema: Reported with baloxavir marboxil. Discontinue if a hypersensitivity reaction occurs. (4)
• Bronchospasm: Zanamivir carries a specific risk of serious bronchospasm, including in patients without a prior history of airway disease, and is not recommended for patients with underlying asthma or COPD. Zanamivir is avoided in patients with reactive airway disease, and a fast-acting bronchodilator should be available if it is used in a patient with any airway disease. (2)

Drug-specific effects

• Oseltamivir: The specific neuropsychiatric monitoring recommendation and the H275Y resistance concern are unique among this drug's own labelling emphasis, reflecting both its broad paediatric use and its dominant real-world usage volume. (1)
• Zanamivir: Inhalation route carries the class's specific bronchospasm warning, not shared by the oral or IV agents. (2)
• Peramivir: Its efficacy has specifically not been established in patients with influenza serious enough to require hospitalisation, a limitation stated directly in its own label rather than a general class caveat. (3)
• Baloxavir marboxil: Uniquely subject to a food/polyvalent-cation interaction that meaningfully lowers drug absorption if not avoided around dosing. (4)

Contraindications, precautions and interactions

Contraindications

• Oseltamivir: known serious hypersensitivity to oseltamivir or any component of the product. (1)
• Baloxavir marboxil: history of hypersensitivity to baloxavir marboxil or any of its ingredients. (4)

Precautions

• Zanamivir is not recommended for patients with underlying airway disease such as asthma or COPD because of the risk of serious bronchospasm. (2)
• Patients on any of these drugs, especially paediatric patients on oseltamivir, are monitored for signs of abnormal behaviour during the acute illness. (1)
• Peramivir's efficacy is not established in patients sick enough to need hospitalisation, which is a caution about expected benefit rather than a safety contraindication. (3)

Drug interactions

• Dairy products, calcium-fortified beverages, polyvalent-cation-containing laxatives and antacids: Chelate baloxavir marboxil and reduce its absorption; co-administration around the dose is avoided. (4)
• Live attenuated influenza vaccine: Antiviral activity against the vaccine virus is a general consideration with any influenza antiviral used near the time of live vaccine administration and is addressed in current immunisation guidance rather than restated here in detail. (5)

Resistance mechanisms

Comparison tables

High-yield exam pearls

• Neuraminidase inhibitors act at viral release; baloxavir acts at viral transcription — two genuinely different steps of the replication cycle, not two versions of the same idea. (1) (4) This is the single most testable structural fact about the class and explains why baloxavir resistance is mechanistically independent of neuraminidase-inhibitor resistance.
• The 48-hour rule is not a soft suggestion — it is written into the indication itself for acute uncomplicated influenza treatment across this class. (1) (4) Both oseltamivir's and baloxavir's own labels define the treated population as symptomatic no more than 48 hours; starting later moves outside the population the drug was shown to help.
• H275Y is the exam's go-to oseltamivir-resistance mutation, and it became essentially universal in one specific historical seasonal H1N1 lineage before that lineage was replaced. (1) The magnitude (>99% of 2008 US isolates) is a striking, testable number, and the fact that the resistant lineage was later displaced (not eradicated by better drug use) is a subtlety that catches out an oversimplified telling.
• Zanamivir's bronchospasm warning is inhalation-route-specific, not a class-wide adverse effect. (2) Confusing it with a general neuraminidase-inhibitor risk would wrongly restrict oseltamivir or peramivir use in a patient with asthma.
• Amantadine and rimantadine only ever worked against influenza A, never influenza B, because the drugs target the M2 channel that influenza B does not have in the same form. (6) It is a clean example of a mechanism-based spectrum gap that predates and is separate from the resistance story that later ended the adamantanes' clinical use entirely.

Common exam traps

• Trap: Assuming baloxavir is just a longer-acting neuraminidase inhibitor. Actually: It targets an entirely different viral enzyme (the PA endonuclease of the polymerase complex) acting earlier in the replication cycle, which is why baloxavir resistance and neuraminidase-inhibitor resistance are separate, non-overlapping phenomena. (4)
• Trap: Treating amantadine and rimantadine as current first-line influenza options because they still appear in older pharmacology material. Actually: The CDC explicitly does not recommend either drug for influenza treatment or chemoprophylaxis because of high resistance in circulating influenza A strains, and neither has ever covered influenza B. (5) (6)
• Trap: Assuming zanamivir's bronchospasm risk applies to oral or IV neuraminidase inhibitors too. Actually: The warning is specific to the inhaled route and the direct airway exposure it produces; it is not stated as a class-wide risk in the oseltamivir or peramivir labels. (2)
• Trap: Believing the 48-hour window means these drugs are useless after 48 hours in every patient. Actually: The labelled indication for uncomplicated outpatient illness is built around that window, but CDC guidance notes hospitalised patients with severe or progressive disease may still be treated afterward, since the trial population and the sickest inpatient population are not identical. (5)

Self-test questions

Answers are hidden until you open them. These questions are written from this page's cited content and are for study only — they are not clinical guidance.

1. What viral enzyme do oseltamivir, zanamivir and peramivir all inhibit?

   • The PA endonuclease of the viral polymerase
   • Viral neuraminidase
   • The M2 ion channel
   • Viral haemagglutinin
   Show answer

   Answer: Viral neuraminidase

   All three are neuraminidase inhibitors: they block the enzyme that cleaves sialic acid to release newly assembled virions from the infected cell surface. (1) (2) (3)

2. How does baloxavir marboxil's mechanism differ from that of the neuraminidase inhibitors?

   • It also inhibits neuraminidase but with longer duration
   • It inhibits the endonuclease activity of the viral polymerase acidic protein, blocking cap-snatching and mRNA transcription
   • It blocks the M2 ion channel
   • It has no antiviral mechanism and works only symptomatically
   Show answer

   Answer: It inhibits the endonuclease activity of the viral polymerase acidic protein, blocking cap-snatching and mRNA transcription

   Baloxavir inhibits the PA endonuclease, an earlier step in the replication cycle (viral transcription) than the neuraminidase inhibitors' target (viral release). (4)

3. Which resistance mutation is specifically associated with oseltamivir and became dominant in one historical seasonal influenza lineage?

   • I38T
   • M2 S31N
   • H275Y
   • PA/E23K
   Show answer

   Answer: H275Y

   H275Y in the neuraminidase gene reduces oseltamivir binding and was found in more than 99% of US-circulating 2008 seasonal H1N1 isolates. (1)

4. Why is zanamivir avoided in patients with asthma or COPD?

   • It causes hepatotoxicity in these patients
   • It carries a specific risk of serious bronchospasm because it is delivered by oral inhalation
   • It is ineffective against influenza in these patients
   • It requires an IV line that these patients cannot tolerate
   Show answer

   Answer: It carries a specific risk of serious bronchospasm because it is delivered by oral inhalation

   Zanamivir's own label carries a specific warning about serious bronchospasm, including in patients without prior airway disease, and it is not recommended for patients with asthma or COPD. (2)

5. What is the current status of amantadine and rimantadine for influenza?

   • First-line therapy for influenza A and B
   • Not recommended for treatment or chemoprophylaxis because of high resistance among circulating influenza A viruses, and never active against influenza B
   • Reserved for hospitalised patients only
   • Recommended only in children under 2 weeks of age
   Show answer

   Answer: Not recommended for treatment or chemoprophylaxis because of high resistance among circulating influenza A viruses, and never active against influenza B

   The CDC states these adamantanes are not recommended because of high-level resistance in circulating influenza A, and they were never active against influenza B, which has a structurally different M2-equivalent protein. (5) (6)

6. Within what time frame from symptom onset is treatment with oseltamivir or baloxavir indicated for uncomplicated outpatient influenza?

   • 7 days
   • 48 hours
   • 24 hours only
   • There is no time limit specified in the label
   Show answer

   Answer: 48 hours

   Both labels define the treated population for acute uncomplicated influenza as patients symptomatic for no more than 48 hours, reflecting where the clinical trial benefit was demonstrated. (1) (4)

Frequently asked questions

References

1. TAMIFLU (oseltamivir phosphate) — prescribing information DailyMed, U.S. National Library of Medicine
2. RELENZA (zanamivir) — prescribing information DailyMed, U.S. National Library of Medicine
3. RAPIVAB (peramivir) — prescribing information DailyMed, U.S. National Library of Medicine
4. XOFLUZA (baloxavir marboxil) — prescribing information DailyMed, U.S. National Library of Medicine
5. Influenza Antiviral Medications: Summary for Clinicians Centers for Disease Control and Prevention
6. Amantadine StatPearls Publishing / NCBI Bookshelf

Related drug classes

• Azole antifungals
• Other antifungals: polyenes, echinocandins and allylamines

Back to the Antivirals, antifungals and antiparasitics classification · Pharmacology Study Corner